Mononuclear Therapeutics

What Mononuclear Therapeutics does

Mononuclear Therapeutics Limited (MonoTx) is a privately held Hong Kong-based biotechnology company founded in 2016 that operates an integrated umbilical cord blood (UCB)-derived therapeutic platform. The company runs Hong Kong's first AABB-accredited public umbilical cord blood mononuclear cell (UCBMNC) bank, storing more than 10,000 high-quality cord blood units collected from three Hong Kong hospitals (Prince of Wales, Kwong Wah, and Hong Kong Sanatorium) and screened across multiple infectious disease markers. MonoTx holds AABB accreditation (maintained since 2019, most recently re-assessed in October 2025), FDA registration as a Human Cell & Tissue Establishment under 21 CFR Part 1271, and affiliation with the World Marrow Donor Association (WMDA).

The company's core technology combines AABB-accredited cord blood banking with an automated, closed, GMP-compatible processing system and a proprietary PEG-based precipitation method for isolating exosomes from cord blood plasma (protected by US Patent 12,576,201 B2, granted March 2026, with parallel filings in Europe, China, Hong Kong, and India). This platform yields three research-grade product lines: Human Cord Blood Mononuclear Cells (MNC, Cat# UBP-006.1, 20 million cells per aliquot), Exosome Rich Plasma (ERP®, Cat# UBP-004.1, >10^9 particles per vial), and Lyophilized Cord Blood Platelet Lysate (PLT, Cat# UBP-003.1). The PEG process claims >90% exosome recovery and >10^10 particles/mL concentration, scalable from 1 mL to multi-liter volumes.

MonoTx generates revenue through three streams: (1) sales of research-grade MNC, ERP®, and PLT products to research institutions and biotech companies via direct enterprise sales and an e-commerce storefront on monotx.com; (2) supply of commercial-grade ERP® as an ingredient to aesthetic and skincare companies for incorporation into cosmeceutical formulations (the primary near-term revenue source); and (3) non-dilutive grant funding from the Hong Kong Innovation and Technology Fund (ITF). The company's pipeline targets neurological indications (spinal cord injury, stroke, neonatal hypoxic-ischemic encephalopathy) via MNC therapy, ophthalmological conditions (dry eye, glaucoma, AMD) via ERP®, and hematopoietic stem cell transplantation. Cord blood banking operations are housed in a Grade C cleanroom facility at Hong Kong Science Park, with an additional office at the HKSTP Shenzhen Branch in Futian, China.

Name

Mononuclear Therapeutics

Legal name

Mononuclear Therapeutics Limited

Website

https://monotx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Mononuclear Therapeutics is a Hong Kong-based biotech that operates an AABB-accredited public umbilical cord blood bank and produces clinical-grade mononuclear cells, exosome-rich plasma, and platelet lysate for research institutions, aesthetic companies, and transplant centers.

Ownership category

akta.pro rank

Product category

Cellular Therapy & Regenerative Medicine

NAICS

Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

• Cord blood banking
• Cellular therapy products
• Exosome isolation
• Regenerative medicine
• Mononuclear cell therapy

Headquarters

HQ city

Sha Tin

HQ country

Hong Kong SAR China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Research Product Sales: Sale of research-grade cord blood products including Human Cord Blood Mononuclear Cells (MNC, Cat# UBP-006.1, 20 million cells/aliquot), Exosome Rich Plasma ERP® (Cat# UBP-004.1, >10^9 particles), and Lyophilized Human Cord Blood Platelet Lysate (PLT, Cat# UBP-003.1). Products are sold directly to research institutions for use in immunology, hematopoietic disease, transplant therapy, wound healing, and regenerative medicine research.
2. ERP® Supply to Aesthetic/Cosmetics Companies: Near-term revenue generated through supply of ERP® (Exosome Rich Plasma) to aesthetic and skincare companies for incorporation into aesthetic and skincare products. Commercial-grade ERP® is supplied as an ingredient for cosmeceutical formulations.
3. Government Funding (ITF): Received funding support from Hong Kong Government's Innovation and Technology Fund (ITF) to establish the UCBMNC bank and conduct MNC-related research and clinical studies. This non-dilutive funding supports platform development.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Mononuclear Therapeutics (MonoTx) operates an integrated umbilical cord blood (UCB)-derived therapeutic platform that combines AABB-accredited cord blood banking with proprietary PEG-based manufacturing technology to produce clinical-grade mononuclear cells (MNC), plasma-derived exosomes (ERP®), and lyophilized platelet lysate (PLT). The platform uses an automated closed-system, GMP-compatible process to fractionate cord blood into cellular and cell-free components for sale as research-grade products to biotech and academic customers, as well as ingredient supply to aesthetic/cosmetics companies.

Product overview

MonoTx® operates an integrated human umbilical cord blood (UCB)-derived therapeutic platform that combines AABB-accredited cord blood banking with proprietary manufacturing technology to produce clinical-grade mononuclear cells (MNCs), plasma-derived exosomes (ERP®), and platelet lysate (PLT) products. The platform employs automated, closed-system, GMP-compatible processing to fractionate fresh umbilical cord blood into cellular components (MNCs for neurological repair applications) and cell-free plasma (source material for ERP® exosome products). Their product portfolio includes MNC for spinal cord injury and HIE research, ERP® for ophthalmology and wound healing applications, and PLT as a cell culture supplement. The platform is protected by a proprietary PEG-based exosome isolation technology with US patent protection.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Cord Blood Mononuclear Cells (MNC)

Quantifiable outcome

• >90% exosome recovery rate from plasma-derived exosomes, substantially exceeding ultracentrifugation-based methods
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Dimension Plus / Keith LamminorGTM or Marketing Partner · 18 August 2022New media artist Keith Lam and his creative team Dimension Plus created 'Mononuclear Vitality' artwork inspired by MonoTx's mononuclear cell therapy. The artwork was featured at META-PARADE, exploring the symbolism of renewal and restoration through the dynamic transformation of mononuclear cells.
• Hong Kong Science and Technology Parks Corporation (HKSTP)coreStrategic or Co-development Partner · 8 January 2020MonoTx is a partner company of HKSTP, located at Hong Kong Science Park. HKSTP provides ecosystem support, infrastructure, and promotional platforms for biotech companies. HKSTP's BioMedical Technology Cluster supports MonoTx's development, with Prof. W. John Kao (Head of BioMedical Technology Cluster) publicly congratulating MonoTx on its AABB accreditation and supporting its vision to make Hong Kong Asia's biotech hub.
• Chinese University of Hong Kong (CUHK)coreStrategic or Co-development Partner · 8 January 2020MonoTx collaborates with CUHK to collect cord blood donations and is conducting a preclinical animal study of MNCs to treat neonatal hypoxic ischemic encephalopathy (HIE). CUHK's Prof. Chi Kong Li serves as Medical Director and Prof. Tak Yeung Leung serves as Medical Director for HPC/Apheresis.
• World Marrow Donor Association (WMDA)coreOthersMonoTx cord blood bank is affiliated with the WMDA, connecting it to the global network of stem cell donor registries and cord blood banks for international collaboration and matching.
• Prince of Wales HospitalcoreChannel Partner/ Reseller/ DistributorLargest childbirth center in Hong Kong where donated cord blood is collected for MonoTx's public cord blood bank. MonoTx receives cord blood units from this hospital for processing and banking.
• Kwong Wah HospitalminorChannel Partner/ Reseller/ DistributorOne of the participating Hong Kong hospitals for cord blood collection, contributing to MonoTx's public cord blood bank.
• Hong Kong Sanatorium HospitalminorChannel Partner/ Reseller/ DistributorOne of the participating Hong Kong hospitals for cord blood collection, contributing to MonoTx's public cord blood bank.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Future Health Biobank: UK-based cord blood and tissue bank with international operations. Comparable in cord blood collection, processing, and storage services, but primarily serves European and Middle Eastern markets rather than Asia.

Emerging players

• Capricor Therapeutics: Cellular and exosome-based therapeutics developer with a lead program (CAP-1002) in Duchenne muscular dystrophy. Comparable in leveraging extracellular vesicles/exosomes as therapeutic modalities for neurological and rare disease indications.
• Celularity: Placenta-derived cellular and exosome therapeutics company with overlapping interest in placental/perinatal cell therapies and exosome-based regenerative products. Comparable in technology approach (perinatal tissue-derived biologics) but operates at a later clinical stage.
• ExoCoBio: South Korea-based exosome therapeutics and aesthetics company developing MSC-derived exosome products for dermatology and regenerative medicine. Directly comparable in commercializing exosomes for cosmetic/skincare indications and is a near-term competitor in the same aesthetics channel MonoTx is targeting.

Direct peers

• StemCyte: Direct peer in umbilical cord blood banking and MNC/cord blood-derived therapies. Shares operational overlap with MonoTx including cord blood collection, AABB accreditation, and supply to transplant programs; CEO Kenneth Giacin and CCO Charles Lu previously led StemCyte operations.
• ViaCord (Revvity): Direct peer in private and family cord blood banking with an AABB-accredited processing facility. Competes in the same cord blood storage and research-grade product categories as MonoTx.
• Cryo-Cell International: Direct peer operating AABB-accredited cord blood and tissue banking services globally. Comparable in providing family and public banking of cord blood for both transplant and regenerative medicine applications.
• Cord Blood Registry (CBR) by California Cryobank: One of the largest family cord blood banks in the US, offering cord blood and cord tissue banking plus research-grade products. Directly comparable in target market (parents seeking biological insurance) and in supplying research institutions.

Broad incumbents

• Pluristem Therapeutics: Placenta-derived cell therapy developer with allogeneic PLX cell products in clinical trials for multiple indications. Comparable as a placenta/perinatal tissue-derived cell therapy competitor with broader pipeline scale.
• Mesoblast: Commercial-stage cellular medicine company with mesenchymal lineage cell therapies in late-stage clinical development for inflammatory and cardiovascular indications. Comparable as a broader incumbent in cell-based regenerative medicine targeting multiple disease areas.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/monotx

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mononuclear Therapeutics